Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention

Platelet glycoprotein IIb/IIIa inhibitors (GPIs) have been part of the adjuvant treatment of acute coronary syndrome for years. However, real-life data regarding the efficacy and safety of GPIs under the current indications are lacking in the setting of potent platelet inhibition. The objectives wer...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Pablo Revilla-Martí, Jose A. Linares-Vicente, Ana Martínez Labuena, Octavio Jiménez Melo, Paula Morlanes Gracia, Daniel Meseguer González, Antonela Lukic, Borja Simó Sánchez, Jose R. Ruiz Arroyo
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Taylor & Francis Group 2022-02-01
Ráidu:	Platelets
Fáttát:	abciximab percutaneous coronary intervention platelet aggregation inhibitors st elevation myocardial infarction tirofiban
Liŋkkat:	http://dx.doi.org/10.1080/09537104.2021.1881953
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!